WO2023042104 - NOVEL TRANSCRIPTION FACTORS
National phase entry:
Publication Number
WO/2023/042104
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058691
International Filing Date
15.09.2022
Title **
[English]
NOVEL TRANSCRIPTION FACTORS
[French]
NOUVEAUX FACTEURS DE TRANSCRIPTION
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
FERGUSON, Keith Everett
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
HROMADKA, Stephanie Viani
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
TAO, Xu E.
28 Blueberry Ln
Lexington, Massachusetts 02420, US
Priority Data
63/245,084
16.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2485 | |
| EPO | Filing, Examination | 14512 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 8960 |
Total: 27118 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to novel transcription factors for modulating the expression of gene of interest, by fusing to a DNA binding domain that targets the gene of interest.[French]
La présente invention concerne de nouveaux facteurs de transcription pour moduler l'expression d'un gène d'intérêt, par fusion à un domaine de liaison à l'ADN qui cible le gène d'intérêt.